Altimmune, Inc.
ALT- 1D
- -2.9%
Altimmune, Inc. in brief
Altimmune, Inc. is a listed company in the Biotechnology industry, based in Maryland, USA. It was founded in 1997. Its market value was $459 M on 16 October 2026, which makes it the 12,938th largest listed company in the world and the 2,582nd largest in the USA on this site. In the year to December 2025 it had sales of $0 M and a net loss of $88 M. It employs about 55 people and Jerome Benedict Durso is its chief executive. Its shares trade under the symbol ALT (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Altimmune, Inc.
Altimmune, Inc. is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases and intranasal vaccines. The company annual revenue is 8.1 million USD and total assets are 245 million USD as on 2020. The headquarters is in USA.
Altimmune, Inc. timeline
- 1997
- 🏁· approximateFounded
- 2005
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2007
- ✎Renamed Pharmathene, IncFormerly Healthcare Acquisition Corp.
- 2017
- ✎Renamed Altimmune, Inc.Formerly Pharmathene, Inc.
- 2018
- •Legal Entity Identifier issuedLEI 549300EOYCQ8SW3NVE64 registered.
Events of Altimmune, Inc. from Wikidata, SEC EDGAR and the GLEIF LEI register. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,355 (Jan 2020) · #2,993 (Jan 2021) · #3,336 (Jan 2022) · #2,220 (Dec 2022) · #3,800 (Jul 2023) · #2,361 (Jan 2024) · #1,360 (Mar 2026) · #2,451 (Aug 2026) · #2,560 (Oct 2026) · #2,585 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- 11480.8×
- Price / book
- 2.0×
- Free cash flow yield
- -14.7%
- Net margin
- -220225.0%
- Operating margin
- -236225.0%
- Return on equity
- -39.2%
- Liabilities / assets
- 19.7%
- Net debt
- $-9M
- Revenue growth
- +100.0%
- R&D / revenue
- 166075.0%
- Revenue per employee
- $1 K
- Profit per employee
- $-1.6 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $0M | +100.0% | $-94M | $-88M | -220225.0% |
| Dec 2024 | $0M | -95.3% | $-103M | $-95M | -475300.0% |
| Dec 2023 | $0M | — | $-96M | $-88M | -20569.8% |
| Dec 2022 | — | — | $-88M | $-85M | — |
| Dec 2021 | $4M | -46.2% | $-97M | $-97M | -2201.6% |
| Dec 2020 | $8M | +41.2% | $-55M | $-49M | -598.8% |
| Dec 2019 | $6M | -43.9% | $-21M | $-21M | -353.8% |
| Dec 2018 | $10M | — | $-43M | $-39M | -379.2% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-68M | $0M | $-68M | $-1.00 | — |
| Dec 2024 | $-80M | — | — | $-1.34 | — |
| Dec 2023 | $-76M | $0M | $-76M | $-1.66 | — |
| Dec 2022 | $-63M | $0M | $-63M | $-1.81 | — |
| Dec 2021 | $-78M | $12M | $-90M | $-2.35 | — |
| Dec 2020 | $-34M | $0M | $-35M | $-1.91 | — |
| Dec 2019 | $-10M | $0M | $-10M | $-1.60 | — |
| Dec 2018 | $-9M | $1M | $-10M | $-15.16 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-32M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 12, 202610-QQuarterly report · period to Sep 2026
- Nov 12, 20268-KCurrent reportResults of operations
- Oct 29, 20268-KCurrent reportNew financial obligation
- Oct 27, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Sep 29, 20268-KCurrent reportDirectors or officers changed
- Aug 12, 202610-QQuarterly report · period to Jun 2026
- Aug 12, 20268-KCurrent reportResults of operations
- Jul 28, 20268-KCurrent reportRegulation FD disclosure · Other events
- Jun 16, 20268-KCurrent reportOther events
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
- Apr 24, 20268-KCurrent reportMaterial agreement
Official filings of Altimmune, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $0 M
- Operating income
- $-94 M
- Net income
- $-88 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $280 M
- Total liabilities
- $55 M
- Total equity
- $225 M
As of December-2025
Top 100 institutional investors in Altimmune, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 20,960,259 | +574,975 (+2.82%) | 10.77% | $60 M | Nov 13, 2026 |
| 2 | Deep Track Capital, LP | 19,250,000 | 0 (0.00%) | 9.89% | $55 M | Nov 16, 2026 |
| 3 | State Street Corp | 8,356,408 | -3,742,132 (-30.93%) | 4.29% | $24 M | Nov 12, 2026 |
| 4 | Vanguard Portfolio Management LLC | 8,107,554 | +777,289 (+10.60%) | 4.17% | $23 M | Nov 13, 2026 |
| 5 | Vanguard Capital Management LLC | 7,812,919 | -364,833 (-4.46%) | 4.02% | $22 M | Nov 13, 2026 |
| 6 | Viking Global Investors LP | 6,700,000 | 0 (0.00%) | 3.44% | $19 M | Nov 16, 2026 |
| 7 | Ra Capital Management, L.P. | 6,500,000 | 0 (0.00%) | 3.34% | $19 M | Nov 16, 2026 |
| 8 | Marshall Wace, LLP | 5,431,302 | -1,409,753 (-20.61%) | 2.79% | $16 M | Nov 13, 2026 |
| 9 | Geode Capital Management, LLC | 4,884,491 | -126,823 (-2.53%) | 2.51% | $14 M | Nov 6, 2026 |
| 10 | Two Sigma Investments, LP | 4,241,069 | +1,859,927 (+78.11%) | 2.18% | $12 M | Nov 16, 2026 |
| 11 | Trails Edge Capital Partners, LP | 4,230,000 | +1,570,000 (+59.02%) | 2.17% | $12 M | Nov 16, 2026 |
| 12 | Millennium Management LLC | 3,844,940 | +535,818 (+16.19%) | 1.98% | $11 M | Nov 16, 2026 |
| 13 | Woodline Partners LP | 3,400,312 | 0 (0.00%) | 1.75% | $10 M | Nov 16, 2026 |
| 14 | Goldman Sachs Group Inc | 2,479,456 | +265,006 (+11.97%) | 1.27% | $7 M | Nov 16, 2026 |
| 15 | Nuveen, LLC | 2,147,105 | -258,249 (-10.74%) | 1.10% | $6 M | Nov 10, 2026 |
| 16 | Weiss Asset Management LP | 2,029,320 | +498,517 (+32.57%) | 1.04% | $6 M | Nov 16, 2026 |
| 17 | Great Point Partners LLC | 1,741,232 | 0 (0.00%) | 0.89% | $5 M | Nov 16, 2026 |
| 18 | Nantahala Capital Management, LLC | 1,720,000 | -1,280,000 (-42.67%) | 0.88% | $5 M | Nov 13, 2026 |
| 19 | FMR LLC | 1,612,459 | +863,485 (+115.29%) | 0.83% | $5 M | Nov 10, 2026 |
| 20 | Point72 Asset Management, L.P. | 1,458,907 | +972,023 (+199.64%) | 0.75% | $4 M | Nov 16, 2026 |
| 21 | Northern Trust Corp | 1,458,532 | -140,694 (-8.80%) | 0.75% | $4 M | Nov 16, 2026 |
| 22 | Susquehanna International Group, LLP | 1,423,141 | +692,063 (+94.66%) | 0.73% | $4 M | Nov 16, 2026 |
| 23 | Bank Of America Corp /de/ | 1,292,126 | +534,207 (+70.48%) | 0.66% | $4 M | Nov 16, 2026 |
| 24 | Vanguard Fiduciary Trust Co | 1,122,754 | -170,247 (-13.17%) | 0.58% | $3 M | Nov 13, 2026 |
| 25 | UBS Group AG | 951,139 | +84,754 (+9.78%) | 0.49% | $3 M | Nov 10, 2026 |
Show all 100: investors 26 to 100
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | Barclays PLC | 922,127 | +570,540 (+162.28%) | 0.47% | $3 M | Nov 6, 2026 |
| 27 | Morgan Stanley | 850,208 | +91,773 (+12.10%) | 0.44% | $2 M | Nov 13, 2026 |
| 28 | Ghisallo Capital Management LLC | 750,000 | 0 (0.00%) | 0.39% | $2 M | Nov 16, 2026 |
| 29 | Hennion & Walsh Asset Management, Inc. | 744,997 | +226,799 (+43.77%) | 0.38% | $2 M | Oct 13, 2026 |
| 30 | Squarepoint Ops LLC | 740,634 | +538,254 (+265.96%) | 0.38% | $2 M | Nov 9, 2026 |
| 31 | Citadel Advisors LLC | 693,769 | -289,790 (-29.46%) | 0.36% | $2 M | Nov 16, 2026 |
| 32 | Bank of New York Mellon Corp | 670,825 | -18,888 (-2.74%) | 0.34% | $2 M | Nov 5, 2026 |
| 33 | Tang Capital Management LLC | 666,022 | 0 (0.00%) | 0.34% | $2 M | Nov 16, 2026 |
| 34 | Wellington Management Group LLP | 663,764 | +243,464 (+57.93%) | 0.34% | $2 M | Nov 16, 2026 |
| 35 | Dimensional Fund Advisors LP | 626,553 | -12,883 (-2.01%) | 0.32% | $2 M | Nov 4, 2026 |
| 36 | Charles Schwab Investment Management Inc | 607,885 | -16,614 (-2.66%) | 0.31% | $2 M | Nov 16, 2026 |
| 37 | D. E. Shaw & Co., Inc. | 573,943 | +372,305 (+184.64%) | 0.29% | $2 M | Nov 16, 2026 |
| 38 | BNP Paribas Financial Markets | 460,111 | +88,935 (+23.96%) | 0.24% | $1 M | Nov 12, 2026 |
| 39 | Beirne Wealth Consulting Services, LLC | 421,858 | 0 (0.00%) | 0.22% | $1 M | Oct 19, 2026 |
| 40 | Balyasny Asset Management L.P. | 402,500 | New | 0.21% | $1 M | Nov 16, 2026 |
| 41 | HSBC Holdings PLC | 378,840 | +314,380 (+487.71%) | 0.19% | $1 M | Nov 16, 2026 |
| 42 | Invesco Ltd. | 343,802 | +11,210 (+3.37%) | 0.18% | $1 M | Nov 12, 2026 |
| 43 | HRT Financial LP | 339,221 | New | 0.17% | $1 M | Nov 13, 2026 |
| 44 | Elo Mutual Pension Insurance Co | 328,217 | New | 0.17% | $1 M | Nov 12, 2026 |
| 45 | Rhumbline Advisers | 320,348 | +10,742 (+3.47%) | 0.16% | $1 M | Nov 10, 2026 |
| 46 | Janney Montgomery Scott LLC | 312,710 | +10,100 (+3.34%) | 0.16% | $1 M | Nov 12, 2026 |
| 47 | LMR Partners LLP | 300,000 | 0 (0.00%) | 0.15% | $1 M | Nov 16, 2026 |
| 48 | Steward Partners Investment Advisory, LLC | 267,884 | +1,213 (+0.45%) | 0.14% | $1 M | Nov 13, 2026 |
| 49 | Alps Advisors Inc | 255,875 | +58,501 (+29.64%) | 0.13% | $1 M | Nov 3, 2026 |
| 50 | Brown Wealth Management, LLC | 240,136 | +4,000 (+1.69%) | 0.12% | $1 M | Oct 20, 2026 |
| 51 | Baird Financial Group, Inc. | 237,522 | 0 (0.00%) | 0.12% | $1 M | Nov 13, 2026 |
| 52 | Stifel Financial Corp | 212,106 | +19,738 (+10.26%) | 0.11% | $1 M | Nov 12, 2026 |
| 53 | Commonwealth Equity Services, LLC | 210,431 | -4,143 (-1.93%) | 0.11% | $1 M | Nov 2, 2026 |
| 54 | Rafferty Asset Management, LLC | 193,186 | -31,874 (-14.16%) | 0.10% | $1 M | Nov 13, 2026 |
| 55 | Deutsche Bank AG\ | 169,612 | -25,402 (-13.03%) | 0.09% | $0 M | Nov 6, 2026 |
| 56 | Creative Planning | 161,008 | -57,273 (-26.24%) | 0.08% | $0 M | Nov 2, 2026 |
| 57 | Birchview Capital, LP | 160,964 | +8,283 (+5.43%) | 0.08% | $0 M | Nov 13, 2026 |
| 58 | ExodusPoint Capital Management, LP | 160,762 | New | 0.08% | $0 M | Nov 16, 2026 |
| 59 | Price T Rowe Associates Inc /MD/ | 158,259 | -7,131 (-4.31%) | 0.08% | $0 M | Nov 16, 2026 |
| 60 | Prudential Financial Inc | 156,796 | +121,606 (+345.57%) | 0.08% | $0 M | Nov 16, 2026 |
| 61 | Simplex Trading, LLC | 146,416 | New | 0.08% | $0 M | Nov 4, 2026 |
| 62 | Citigroup Inc | 140,846 | -153,102 (-52.08%) | 0.07% | $0 M | Nov 4, 2026 |
| 63 | LPL Financial LLC | 126,865 | +4,913 (+4.03%) | 0.07% | $0 M | Nov 6, 2026 |
| 64 | Wealth Effects LLC | 125,950 | +3,300 (+2.69%) | 0.06% | $0 M | Oct 23, 2026 |
| 65 | Gsa Capital Partners LLP | 124,380 | New | 0.06% | $0 M | Nov 16, 2026 |
| 66 | Man Group plc | 124,093 | -49,779 (-28.63%) | 0.06% | $0 M | Nov 16, 2026 |
| 67 | Voleon Capital Management LP | 121,729 | +101,014 (+487.64%) | 0.06% | $0 M | Nov 16, 2026 |
| 68 | Virtus Investment Advisers, LLC | 121,584 | -3,779 (-3.01%) | 0.06% | $0 M | Nov 12, 2026 |
| 69 | Susquehanna Portfolio Strategies, LLC | 120,554 | +17,180 (+16.62%) | 0.06% | $0 M | Nov 16, 2026 |
| 70 | Jpmorgan Chase & Co | 113,791 | +7,166 (+6.72%) | 0.06% | $0 M | Nov 12, 2026 |
| 71 | Renaissance Technologies LLC | 108,146 | +36,546 (+51.04%) | 0.06% | $0 M | Nov 12, 2026 |
| 72 | Alliancebernstein L.P. | 107,490 | -33,360 (-23.68%) | 0.06% | $0 M | Nov 16, 2026 |
| 73 | MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | 106,947 | -10,735 (-9.12%) | 0.06% | $0 M | Nov 16, 2026 |
| 74 | Silvercrest Asset Management Group LLC | 103,500 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 75 | Summit Financial Wealth Advisors, LLC | 103,288 | 0 (0.00%) | 0.05% | $0 M | Oct 15, 2026 |
| 76 | ADAR1 Capital Management, LLC | 102,823 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 77 | MetLife Investment Management, LLC | 102,616 | -14,240 (-12.19%) | 0.05% | $0 M | Nov 16, 2026 |
| 78 | Nomura Asset Management International Inc. | 100,000 | 0 (0.00%) | 0.05% | $0 M | Nov 16, 2026 |
| 79 | Leonteq Securities AG | 100,000 | +36,000 (+56.25%) | 0.05% | $0 M | Oct 29, 2026 |
| 80 | Wells Fargo & Company/mn | 87,818 | -129,612 (-59.61%) | 0.05% | $0 M | Nov 16, 2026 |
| 81 | Canada Pension Plan Investment Board | 87,300 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 82 | WINTON GROUP Ltd | 86,900 | +70,800 (+439.75%) | 0.04% | $0 M | Nov 12, 2026 |
| 83 | Corient Private Wealth LP | 85,400 | +31,174 (+57.49%) | 0.04% | $0 M | Nov 16, 2026 |
| 84 | Brevan Howard Capital Management LP | 82,229 | -48,552 (-37.12%) | 0.04% | $0 M | Nov 16, 2026 |
| 85 | Jump Financial, LLC | 81,441 | -108,559 (-57.14%) | 0.04% | $0 M | Nov 13, 2026 |
| 86 | Profund Advisors LLC | 69,238 | -44,360 (-39.05%) | 0.04% | $0 M | Oct 29, 2026 |
| 87 | Ameriprise Financial Inc | 68,719 | +148 (+0.22%) | 0.04% | $0 M | Nov 16, 2026 |
| 88 | Vanguard Global Advisers, LLC | 65,204 | -9,841 (-13.11%) | 0.03% | $0 M | Nov 13, 2026 |
| 89 | AQR Capital Management LLC | 63,485 | -1,157,464 (-94.80%) | 0.03% | $0 M | Nov 16, 2026 |
| 90 | Graham Capital Management, L.P. | 62,614 | +17,674 (+39.33%) | 0.03% | $0 M | Nov 16, 2026 |
| 91 | Police & Firemen's Retirement System of New Jersey | 58,625 | 0 (0.00%) | 0.03% | $0 M | Nov 9, 2026 |
| 92 | New York State Common Retirement Fund | 52,747 | 0 (0.00%) | 0.03% | $0 M | Nov 17, 2026 |
| 93 | Cetera Investment Advisers | 51,675 | -226 (-0.44%) | 0.03% | $0 M | Nov 13, 2026 |
| 94 | Rockefeller Capital Management L.P. | 50,115 | +375 (+0.75%) | 0.03% | $0 M | Nov 13, 2026 |
| 95 | Manufacturers Life Insurance Company, The | 49,299 | -2,737 (-5.26%) | 0.03% | $0 M | Nov 13, 2026 |
| 96 | Russell Investments Group, Ltd. | 44,066 | +370 (+0.85%) | 0.02% | $0 M | Nov 6, 2026 |
| 97 | Tower Research Capital LLC (TRC) | 41,101 | +33,624 (+449.70%) | 0.02% | $0 M | Nov 16, 2026 |
| 98 | Voya Investment Management LLC | 38,625 | -1,158 (-2.91%) | 0.02% | $0 M | Nov 10, 2026 |
| 99 | MML Investors Services, LLC | 36,719 | +2,169 (+6.28%) | 0.02% | $0 M | Nov 13, 2026 |
| 100 | Osaic Holdings, Inc. | 35,678 | +14,600 (+69.27%) | 0.02% | $0 M | Nov 12, 2026 |
Superinvestors holding Altimmune, Inc.
1 of the well-known investors value.today follows, from their newest Form 13F.
- Viking Global Investors · Andreas Halvorsen$19 M · Sep 30, 2026
Mutual funds holding Altimmune, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc. | 8.10 M | $25 M | 4.2% | 0.23% | +86% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 5.75 M | $17 M | 3.0% | <0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 5.16 M | $16 M | 2.7% | 0.02% | +64% | Jun 30, 2026 |
| 🇺🇸 Vanguard Strategic Equity FundThe Vanguard Group, Inc. | 2.52 M | $8 M | 1.3% | 0.06% | +37% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 2.24 M | $7 M | 1.1% | <0.01% | +58% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 2.17 M | $6 M | 1.1% | 0.02% | +68% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 1.87 M | $6 M | 0.96% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors | 1.30 M | $4 M | 0.67% | 0.04% | +40% | Jun 30, 2026 |
| 🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc. | 1.21 M | $3 M | 0.62% | 0.02% | no change | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Core FundBlackRock Advisors, LLC | 1.05 M | $3 M | 0.54% | 0.06% | +74% | May 29, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 988,478 | $3 M | 0.51% | <0.01% | +79% | May 31, 2026 |
| 🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc. | 867,177 | $3 M | 0.45% | 0.08% | +38% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 670,084 | $2 M | 0.34% | 0.01% | +53% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 668,001 | $2 M | 0.34% | 0.13% | +103% | Jun 30, 2026 |
| 🇺🇸 Fidelity Enhanced Small Cap Core ETFFidelity Management & Research Company LLC | 638,025 | $2 M | 0.33% | 0.03% | +11% | Jun 30, 2026 |
| 🇺🇸 Vanguard Health Care Index FundThe Vanguard Group, Inc. | 567,179 | $2 M | 0.29% | <0.01% | +114% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 483,547 | $1 M | 0.25% | 0.02% | +69% | Jul 31, 2026 |
| 🇺🇸 Vanguard Market Neutral FundThe Vanguard Group, Inc. | 400,755 | $1 M | 0.21% | 0.20% | +17% | Jun 30, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 371,571 | $1 M | 0.19% | 0.02% | +75% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 357,417 | $1 M | 0.18% | <0.01% | +79% | May 31, 2026 |
| 🇺🇸 iShares Core S&P Total U.S. Stock Market ETFBlackRock Fund Advisors | 355,966 | $1 M | 0.18% | <0.01% | +81% | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 290,374 | $1 M | 0.15% | <0.01% | +92% | May 31, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 277,849 | $1 M | 0.14% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc. | 276,644 | $1 M | 0.14% | 0.05% | no change | Jun 30, 2026 |
| 🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC | 275,123 | $1 M | 0.14% | 0.16% | +11% | Jul 31, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 264,710 | $1 M | 0.14% | 0.02% | +70% | Jul 31, 2026 |
| 🇺🇸 BlackRock Advantage Small Cap Growth FundBlackRock Funds | 233,173 | $1 M | 0.12% | 0.09% | +29% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 216,279 | $1 M | 0.11% | 0.02% | +63% | Jun 30, 2026 |
| 🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP | 210,694 | $1 M | 0.11% | <0.01% | −5.7% | Jul 31, 2026 |
| 🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC | 183,869 | $1 M | 0.09% | 0.02% | +8.2% | Jul 31, 2026 |
| 🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP | 167,692 | $0 M | 0.09% | <0.01% | −60% | Jul 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 142,900 | $0 M | 0.07% | 0.02% | +171% | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 141,468 | $0 M | 0.07% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 ALPS Medical Breakthroughs ETFALPS Advisors, Inc. | 134,076 | $0 M | 0.07% | 0.25% | +44% | May 31, 2026 |
| 🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc. | 140,831 | $0 M | 0.07% | <0.01% | +117% | Jul 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 121,751 | $0 M | 0.06% | 0.02% | +50% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC | 113,443 | $0 M | 0.06% | <0.01% | +59% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 102,890 | $0 M | 0.05% | 0.02% | +61% | Jun 30, 2026 |
| 🇺🇸 Nomura Healthcare FundDelaware Management Company | 100,000 | $0 M | 0.05% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 99,551 | $0 M | 0.05% | <0.01% | +30% | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 94,001 | $0 M | 0.05% | <0.01% | +63% | Jun 30, 2026 |
| 🇺🇸 Nuveen Equity Index FundTeachers Advisors, LLC | 99,727 | $0 M | 0.05% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC | 90,074 | $0 M | 0.05% | 0.04% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 94,969 | $0 M | 0.05% | 0.02% | +68% | Jul 31, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 80,290 | $0 M | 0.04% | 0.01% | +85% | Jun 30, 2026 |
| 🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors | 77,572 | $0 M | 0.04% | <0.01% | +9.9% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 74,612 | $0 M | 0.04% | <0.01% | +14% | May 31, 2026 |
| 🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC | 72,116 | $0 M | 0.04% | <0.01% | +66% | Jul 31, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 66,249 | $0 M | 0.03% | 0.02% | +58% | Jun 30, 2026 |
| 🇺🇸 Biotechnology Ultrasector ProfundProFund Advisors LLC | 77,039 | $0 M | 0.04% | 0.11% | — | Apr 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 60,560 | $0 M | 0.03% | <0.01% | +157% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 57,050 | $0 M | 0.03% | 0.02% | +69% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 53,983 | $0 M | 0.03% | 0.01% | +57% | May 31, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap Fund, Inc.BlackRock Advisors, LLC | 54,155 | $0 M | 0.03% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 51,100 | $0 M | 0.03% | <0.01% | +15% | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 44,584 | $0 M | 0.02% | 0.06% | +91% | Jun 30, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 44,183 | $0 M | 0.02% | 0.01% | +40% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 43,844 | $0 M | 0.02% | 0.02% | +71% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 40,851 | $0 M | 0.02% | 0.02% | +72% | Jun 30, 2026 |
| 🇺🇸 Strategic Advisers U.S. Total Stock FundStrategic Advisers LLC | 36,028 | $0 M | 0.02% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 38,622 | $0 M | 0.02% | <0.01% | +55% | Jul 31, 2026 |
| 🇺🇸 GMO U.S. Equity FundGrantham, Mayo, Van Otterloo & Co. LLC | 35,659 | $0 M | 0.02% | 0.05% | −43% | May 31, 2026 |
| 🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP | 34,439 | $0 M | 0.02% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 31,195 | $0 M | 0.02% | 0.02% | +72% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 31,031 | $0 M | 0.02% | 0.02% | new | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 30,317 | $0 M | 0.02% | 0.02% | +103% | Jun 30, 2026 |
| 🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC | 30,070 | $0 M | 0.02% | 0.02% | +55% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 26,807 | $0 M | 0.01% | 0.02% | +73% | Jun 30, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC | 24,605 | $0 M | 0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Dimensional U.S. Equity Market ETFDimensional Fund Advisors LP | 25,408 | $0 M | 0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 23,594 | $0 M | 0.01% | 0.02% | +78% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 3000 ETFBlackRock Fund Advisors | 22,987 | $0 M | 0.01% | <0.01% | −0.8% | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 23,277 | $0 M | 0.01% | 0.02% | +131% | Jul 31, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 21,218 | $0 M | 0.01% | <0.01% | +44% | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 18,039 | $0 M | <0.01% | 0.02% | +69% | Jun 30, 2026 |
| 🇺🇸 JNL/DFA U.S. Small Cap FundJackson National Asset Management, LLC | 17,801 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 17,574 | $0 M | <0.01% | 0.04% | new | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 17,598 | $0 M | <0.01% | 0.02% | +74% | Jul 31, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 15,867 | $0 M | <0.01% | 0.02% | +62% | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 13,643 | $0 M | <0.01% | 0.02% | +76% | Jun 30, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 13,155 | $0 M | <0.01% | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 11,800 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 11,582 | $0 M | <0.01% | <0.01% | +47% | May 31, 2026 |
| 🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC | 10,948 | $0 M | <0.01% | <0.01% | +64% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 9,946 | $0 M | <0.01% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC | 9,834 | $0 M | <0.01% | 0.02% | no change | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 9,800 | $0 M | <0.01% | <0.01% | +20% | Jun 30, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 9,521 | $0 M | <0.01% | <0.01% | +2114% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity Market ETFDimensional Fund Advisors LP | 9,653 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 8,939 | $0 M | <0.01% | <0.01% | −1.7% | Jun 30, 2026 |
| 🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc. | 7,696 | $0 M | <0.01% | <0.01% | −4.1% | Jun 30, 2026 |
| 🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP | 8,167 | $0 M | <0.01% | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 6,983 | $0 M | <0.01% | <0.01% | +76% | Jun 30, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 6,838 | $0 M | <0.01% | <0.01% | +418% | Jul 31, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 6,144 | $0 M | <0.01% | <0.01% | +60% | May 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 5,018 | $0 M | <0.01% | <0.01% | +126% | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 4,861 | $0 M | <0.01% | <0.01% | −11% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 4,804 | $0 M | <0.01% | <0.01% | −12% | May 31, 2026 |
| 🇺🇸 AZL DFA U.S. Core Equity FundAllianz Investment Management LLC | 4,823 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 SA U.S. Small Company FundFocus Advisor Solutions, LLC | 4,035 | $0 M | <0.01% | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 100 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Altimmune, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Richard Thomas MenziusoPrincipal Accounting Officer | Buy | +10,000 | $1.419 | $14 K | 10,000 | Form 4 |
| filed | Gregory L. WeaverChief Financial Officer | Buy | +10,000 | $1.620 | $16 K | 73,005 | Form 4 |
| filed | Jerome Benedict DursoPresident and CEO, Director | Buy | +30,700 | $1.619 | $50 K | 93,200 | Form 4 |
| filed | Wayne PisanoDirector | Buy | +10,000 | $1.635 | $16 K | 58,800 | Form 4 |
| filed | Gregory L. WeaverChief Financial Officer | Option exercise | +18,750 | — | — | 68,677 | Form 4 |
| filed | Gregory L. WeaverChief Financial Officer | Shares withheld for tax | -5,672 | $1.930 | $11 K | 63,005 | Form 4 |
| filed | Christophe Arbet-EngelsChief Medical Officer | Option exercise | +37,500 | — | — | 37,500 | Form 4 |
| filed | Gregory L. WeaverChief Financial Officer | Option exercise | +14,475 | — | — | 54,306 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Altimmune, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-33.33 reverse split
Fails to deliver
- : 11,386 shares at $2.36
- : 631 shares at $2.43
- : 2,146 shares at $2.86
- : 3,623 shares at $3.06
- : 1,957 shares at $3.41
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Altimmune, Inc. scorecard#
Passes 4 of the 15 checks that could be worked out: strongest in financial health (3 of 5), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 16, 2026.
Valuation1 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median2.0×Price to book 2.0× against Biotechnology's median of 2.9×.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-14.7%Free cash flow is -14.7% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-1.00 vs -1.34Diluted EPS -1.00 in fiscal 2025 against -1.34 the year before (report's currency).
- ✗Net income higher than five years earlier-$88 M-$88 M in fiscal 2025 against -$49 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$88 MNet income -$88 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-50.6%-50.6% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 5
- ✓Short-term assets cover short-term liabilities18.6×Current ratio 18.55 at the end of fiscal 2025.
- ✓Debt below equity0.1×Debt to equity 0.15 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $9 M at the end of fiscal 2025.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone1.77Z-score 1.77 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year24.1%Diluted shares up 24.1% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Altimmune, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0.0+105%100% | 0.0−95.3%100% | 0.4—100% | −0.1−102%— | 4.4r4.4−46.1%100% | 8.2+41.1%100% | 5.8−43.8%100% | 10−3.8%100% | 11+232%100% | 3.2—100% | |
| Research and development | 66−19.2%162029% | 82+25.0%411130% | 66−6.7%15446% | 71−5.4%— | 75r75+49.8%1690% | 50+180%608% | 18−3.8%306% | 18+0.3%179% | 18+155%171% | 7.2r4.8—223% | |
| General and administrative | 28+34.0%68532% | 21+15.6%104830% | 18+5.9%4258% | 17+11.2%— | 15r15+16.7%350% | 13+55.4%161% | 8.5−13.0%147% | 9.8+15.5%94.5% | 8.5+19.0%78.8% | 7.1r12—220% | |
| Operating expenses | 95−8.4%230561% | 103+7.1%515960% | 96+9.9%22619% | 88−13.5%— | 101r101+60.9%2298% | 63+131%769% | 27−48.7%470% | 53−15.3%515% | 63+338%585% | 14r16—443% | |
| Operating income | −94—−230461% | −103—−515860% | −96—−22519% | −88—— | −97r−97—−2198% | −55—−669% | −21—−370% | −43—−415% | −52—−485% | −11r−11—−343% | |
| Interest and finance income | 7.5−6.6%18393% | 8.1+9.8%40370% | 7.4+156%1726% | 2.9+1314%— | 0.2r0.2−37.1%4.6% | 0.3−61.8%3.9% | 0.8+272%14.5% | 0.2+376%2.2% | 0.0+4444%0.4% | 0.0—0.0% | |
| Interest expense and finance costs | 1.6+18078%3990% | 0.0−74.3%45.0% | 0.0+338%8.2% | 0.0+60.0%— | 0.0r0.0−46.9%0.1% | 0.0+320%0.1% | 0.0−99.2%0.0% | 0.3+83.2%2.9% | 0.2+321%1.5% | 0.0—1.2% | |
| Net interest income | — | — | — | — | — | — | — | — | — | 0.2—5.2% | |
| Other non-operating income (expense) | 5.7−29.6%13939% | 8.1+8.4%40565% | 7.5+164%1756% | 2.8—— | −0.2r−0.2−152%−4.0% | 0.3−61.9%4.1% | 0.9—15.3% | −2.5—−24.1% | −0.0−481%−0.2% | 0.0r216—0.1% | |
| Income before tax | −89—−216522% | −95—−475295% | −88—−20762% | −85—— | −97r−97—−2202% | −54—−665% | −21—−355% | −45—−439% | −52—−485% | −11r205—−343% | |
| Income tax | −0.7—−1661% | — | — | −0.2—— | — | −5.4—−66.2% | −0.1—−1.0% | −6.1—−59.5% | −5.6—−52.5% | 0r11—0.0% | |
| Net income including minority interests | −88—−214861% | −95—−475295% | −88—−20762% | −85—— | −97r−97—−2202% | −49—−599% | −21—−354% | −39—−379% | −46—−432% | — | |
| Net income attributable to shareholders | −88—−214861% | −95—−475295% | −88—−20762% | −85—— | −97r−97—−2202% | −49—−599% | −21—−354% | −39—−379% | −46—−432% | −11r194—−343% | |
| Earnings per share, basic | -1.00—— | -1.34—— | -1.66—— | -1.81—— | -2.35—— | -1.91—— | -1.60—— | -15.16—— | -118.91r-4.01−4104%— | 2.97—— | |
| Earnings per share, diluted | -1.00—— | -1.34—— | -1.66—— | -1.81—— | -2.35—— | -1.91—— | -1.60—— | -15.16—— | -118.91r-4.01−4131%— | 2.95—— | |
| Shares, weighted average (basic) | 88+24.1%— | 71+33.3%— | 53+13.5%— | 47+13.7%— | 41+61.0%— | 26—— | — | — | — | 65—— | |
| Shares, weighted average (diluted) | 88+24.1%— | 71+33.3%— | 53+13.5%— | 47+13.7%— | 41+61.0%— | 26+95.3%— | 13+368%— | 2.8+549%— | 0.4r13−99.3%— | 66—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 44+18.5%15.6% | 37−72.7%26.5% | 135+21.6%64.1% | 111−41.6%53.7% | 190r190+64.2%86.9% | 116+1193%47.3% | 9.0−73.4%16.6% | 34+285%61.6% | 8.8+205%13.9% | 2.9r154—7.5% | |
| Short-term investments | 230+142%82.1% | 95+51.5%68.2% | 63−15.0%29.8% | 74—35.7% | — | 100+254%40.8% | 28—52.3% | — | — | 67—174% | |
| Other current assets | 3.0+34.2%1.1% | 2.2−68.1%1.6% | 6.9+29.1%3.3% | 5.4−32.6%2.6% | 8.0r8.0+313%3.6% | 1.9+310%0.8% | 0.5−14.2%0.9% | 0.5−44.9%1.0% | 1.0+137%1.6% | 0.4r0.5—1.1% | |
| Current assets | 278+103%99.4% | 137−34.5%98.5% | 210+8.7%99.5% | 193−5.5%93.2% | 204r204−11.3%93.3% | 230+484%93.9% | 39+0.1%72.9% | 39+67.8%71.9% | 23+423%37.2% | 4.5r222—11.7% | |
| Property, plant and equipment | 0.3−24.5%0.1% | 0.4−36.6%0.3% | 0.7−39.8%0.3% | 1.1−25.3%0.5% | 1.4r1.4+37.0%0.7% | 1.1−4.3%0.4% | 1.1−17.8%2.0% | 1.3+123%2.5% | 0.6+239%1.0% | 0.2r0.1—0.5% | |
| Right-of-use (leased) assets | 1.4−13.1%0.5% | 1.6+352%1.2% | 0.4−39.1%0.2% | 0.6−25.3%0.3% | 0.8r0.8−11.7%0.4% | 0.9+29.4%0.4% | 0.7—1.3% | — | — | — | |
| Goodwill | — | — | — | — | — | — | 0—0.0% | 0—0.0% | — | 19r2.3—48.8% | |
| Other intangible assets | — | 0—0.0% | 0−100%0.0% | 120.0%6.0% | 12r12−3.2%5.7% | 13+0.7%5.2% | 13−8.1%23.6% | 14−64.2%25.3% | 39+159%61.4% | 15—38.9% | |
| Total assets | 280+101%100% | 139−33.9%100% | 211+1.8%100% | 207−5.5%100% | 219r219−10.7%100% | 245+353%100% | 54−1.3%100% | 55−13.1%100% | 63+64.1%100% | 38r225—100% | |
| Accounts payable | 2.7+1188%1.0% | 0.2−89.8%0.2% | 2.1−56.9%1.0% | 4.8+136%2.3% | 2.0r2.0+232%0.9% | 0.6+3258%0.2% | 0.0−95.1%0.0% | 0.4+189%0.7% | 0.1−93.6%0.2% | 2.0r0.9—5.2% | |
| Current liabilities | 15+43.3%5.4% | 10−13.8%7.5% | 12−28.8%5.8% | 17−6.7%8.2% | 18r18+52.0%8.4% | 12+206%4.9% | 3.9−13.3%7.3% | 4.5+17.9%8.3% | 3.8−29.8%6.1% | 5.5r205—14.2% | |
| Long-term debt | 34—12.2% | — | — | 4.6+215%2.2% | 1.5r1.5−20.5%0.7% | 1.8−2.0%0.7% | 1.9+0.7%3.4% | 1.9—3.4% | — | — | |
| Lease liabilities (non-current) | 1.1−18.3%0.4% | 1.4+701%1.0% | 0.2−74.0%0.1% | 0.7−40.2%0.3% | 1.1r1.1−23.4%0.5% | 1.5−1.1%0.6% | 1.5—2.7% | — | — | — | |
| Non-current liabilities | — | 5.3+21.2%3.8% | 4.4−4.0%2.1% | 4.6—2.2% | — | — | — | — | — | — | |
| Total liabilities | 55+248%19.7% | 16−4.5%11.3% | 17−23.5%7.9% | 22+9.7%10.5% | 20r20+2.6%9.0% | 19+125%7.8% | 8.5+32.6%15.8% | 6.4−55.1%11.8% | 14+132%22.8% | 6.2r205—16.1% | |
| Retained earnings | −649—−232% | −561—−403% | −466—−221% | −378—−183% | −293r−293—−134% | −186—−76.1% | −137—−254% | −117—−213% | −78—−123% | −31r−30—−81.4% | |
| Shareholders' equity | 225+82.1%80.3% | 124−36.4%88.7% | 194+4.8%92.1% | 185−7.0%89.5% | 199r199−11.8%91.0% | 226r226+396%92.2% | 46−5.8%84.2% | 48+22.6%88.2% | 39+22.3%62.5% | 32r19—83.9% | |
| Total liabilities and equity | 280+101%100% | 139−33.9%100% | 211+1.8%100% | 207−5.5%100% | 219r219−10.7%100% | 245+353%100% | 54−1.3%100% | 55−13.1%100% | 63+64.1%100% | 38r225—100% | |
| Shares outstanding | 111+53.3%— | 72+2.4%— | 71+43.7%— | 49+20.0%— | 41+10.4%— | 37+143%— | 15+68.7%— | 9.1+1392%— | 0.6r18−91.2%— | 6.9r68—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | −0.2−137%— | 0.6+28.5%12.5% | 0.4r0.3+10.7%5.2% | 0.4—6.7% | — | — | — | |
| Share-based compensation | 16+11.7%39210% | 14+35.3%71965% | 11+31.3%2498% | 8.1+46.8%— | 5.5r5.5+114%125% | 2.6+104%31.5% | 1.3+63.5%21.8% | 0.8−46.4%7.5% | 1.4+49.5%13.4% | 1.0r2.2—29.8% | |
| Cash from operating activities | −68—−164720% | −80—−399240% | −76—−17796% | −63—— | −78r−78—−1774% | −34r−34—−419% | −9.6—−166% | −9.4—−90.9% | −20—−188% | −6.4r202—−196% | |
| Capital expenditure | −0.0—−26.8% | — | −0.0—−11.0% | −0.1—— | −12r−12—−275% | −0.2—−2.5% | −0.0—−0.0% | −1.0—−9.4% | −0.1—−1.0% | −0.1r−0.0—−3.9% | |
| Intangible assets bought | — | — | — | — | −0.2r−0.2—−4.4% | −0.1—−1.7% | −0.0—−0.5% | −0.0—−0.4% | −0.1—−0.5% | −0.1—−3.0% | |
| Cash from investing activities | −132—−323105% | −28−307%−141930% | 14—3223% | −73−184%— | 88r88—1985% | −72r−72—−882% | −28—−488% | −1.0−107%−9.7% | 14—128% | −0.2r−67—−6.8% | |
| Debt issued | 35—85366% | — | — | — | — | — | — | — | — | 0.0—0.0% | |
| Shares issued | 174+1638%423739% | 10.0−88.5%49970% | 87+54.2%20329% | 56−13.3%— | 65r65+34.6%1470% | 48—588% | — | 4.3—42.0% | — | 3.8—117% | |
| Cash from financing activities | 207+1959%504493% | 10−88.3%50220% | 86+51.6%20212% | 57−12.8%— | 65r65−69.5%1476% | 213+1604%2608% | 13−61.4%216% | 32+105%314% | 16+218%148% | 5.0r3.8—154% | |
| Exchange-rate effect on cash | — | — | — | — | — | — | — | −0.1−168%−0.5% | 0.1—0.7% | −0.2r−0.0—−5.3% | |
| Change in cash | 6.8—16668% | −98−509%−490950% | 24—5640% | −79−206%— | 74r74−30.5%1687% | 107—1307% | −25−215%−437% | 22+134%213% | 9.4−93.2%87.8% | 138—4277% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | — | — | 0.0*+420%100% | 0.00.0%100% | 0.00.0%100% | 0.00.0%100% | 0.0*−86.5%100% | 0.0—100% | 0.0—100% | 0.0—100% | 0.0*—100% | |
| Research and development | 80+18.4%— | 27+80.6%— | 19+8.2%— | 16+2.3%— | 18*−6.9%70804% | 15−24.5%299200% | 17−18.5%344720% | 16−26.3%316540% | 20*+17.0%395620% | 20—396060% | 21—423100% | 21—429740% | 17*—45700% | |
| General and administrative | 35+53.6%— | 8.7+47.2%— | 7.6+33.1%— | 8.1+34.4%— | 11*+106%40423% | 5.9+18.8%118080% | 5.7+1.7%113820% | 6.0+12.8%119860% | 5.1*+17.5%101800% | 5.0—99380% | 5.6—111900% | 5.3—106240% | 4.3*—11708% | |
| Operating expenses | 115+27.2%— | 36+71.1%— | 26+14.4%— | 24+11.1%— | 29*+16.3%111227% | 21−15.8%417280% | 23−14.3%458540% | 22−18.6%436400% | 25*−26.1%497420% | 25—495440% | 27—535000% | 27—535980% | 34*—90973% | |
| Operating income | −115—— | −36—— | −26—— | −24—— | −29*—−111127% | −21—−417180% | −23—−458440% | −22—−436300% | −25*—−497320% | −25—−495340% | −27—−534900% | −27—−535880% | −34*—−90873% | |
| Interest and finance income | 15+120%— | 4.8+98.6%— | 4.5+300%— | 2.9+87.8%— | 2.4*+55.4%9377% | 2.4+27.0%48520% | 1.1−48.1%22640% | 1.5−36.0%30900% | 1.6*−20.1%31380% | 1.9—38200% | 2.2—43640% | 2.4—48260% | 2.0*—5308% | |
| Interest expense and finance costs | 4.2+447%— | 1.1+126%— | 1.1+316%— | 1.1+106700%— | 0.9*+87500%3369% | 0.5+8150%9900% | 0.3+26300%5280% | 0.00.0%20.0% | 0.0*−50.0%20.0% | 0.0—120% | 0.0—20.0% | 0.0—20.0% | 0.0*—5.4% | |
| Other non-operating income (expense) | 11+82.7%— | 4.1+122%— | 3.4+339%— | 1.7+7.8%— | 1.5*−9.0%5904% | 1.8−4.0%36900% | 0.8−63.1%15520% | 1.6−35.0%31180% | 1.7*−14.9%33720% | 1.9—38440% | 2.1—42100% | 2.4—48000% | 2.0*—5357% | |
| Income before tax | −104—— | −32—— | −23—— | −23—— | −27*—−105223% | −19—−380280% | −22—−442920% | −20—−405120% | −23*—−463600% | −23—−456900% | −25—−492800% | −24—−487880% | −32*—−85516% | |
| Income tax | — | — | — | — | 0*—0.0% | 0*—0.0% | 0*—0.0% | −0.7—−13620% | — | 0—0.0% | 0—0.0% | 0—0.0% | — | |
| Net income including minority interests | −104—— | −32*—— | −23*—— | −23—— | −27*—−105223% | −19*—−380280% | −22*—−442920% | −20—−391500% | −23*—−463600% | −23*—−456900% | −25*—−492800% | −24—−487880% | −32*—−85516% | |
| Net income attributable to shareholders | −104—— | −32—— | −23—— | −23—— | −27*—−105223% | −19—−380280% | −22—−442920% | −20—−391500% | −23*—−463600% | −23—−456900% | −25—−492800% | −24—−487880% | −32*—−85516% | |
| Earnings per share, basic | — | -0.15—— | -0.12—— | -0.18—— | — | -0.21—— | -0.27—— | -0.26—— | — | -0.32—— | -0.35—— | -0.34—— | — | |
| Earnings per share, diluted | — | -0.15—— | -0.12—— | -0.18—— | — | -0.21—— | -0.27—— | -0.26—— | — | -0.32—— | -0.35—— | -0.34—— | — | |
| Shares, weighted average (basic) | 205+130%— | 205+130%— | 185+128%— | 124+64.7%— | — | 89+25.8%— | 81+14.9%— | 76+6.7%— | — | 71—— | 71—— | 71—— | — | |
| Shares, weighted average (diluted) | 205+130%— | 205+130%— | 185+128%— | 124+64.7%— | — | 89+25.8%— | 81+14.9%— | 76+6.7%— | — | 71—— | 71—— | 71—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 29—5.8% | 29−52.8%5.8% | 63−65.6%12.0% | 98+98.8%29.1% | 44+18.5%15.6% | 61+94.6%28.0% | 183+221%96.2% | 49−37.8%31.2% | 37−72.7%26.5% | 31—21.3% | 57—33.0% | 79—41.9% | 135—64.1% | |
| Short-term investments | 236—47.6% | 236+57.9%47.6% | 263—49.9% | 234+132%69.7% | 230+142%82.1% | 150+38.6%68.5% | — | 101−2.3%64.0% | 95+51.5%68.2% | 108—73.0% | 108—62.2% | 103—54.7% | 63—29.8% | |
| Other current assets | 7.0—1.4% | 7.0+59.1%1.4% | 5.2+17.1%1.0% | 1.4−51.2%0.4% | 3.0+34.2%1.1% | 4.4+47.0%2.0% | 4.4+36.3%2.3% | 2.9+2.1%1.9% | 2.2−68.1%1.6% | 3.0—2.0% | 3.2—1.9% | 2.9—1.5% | 6.9—3.3% | |
| Current assets | 276—55.6% | 276+27.3%55.6% | 335+77.7%63.5% | 335+116%99.7% | 278+103%99.4% | 217+48.6%99.2% | 188+10.1%99.0% | 155−17.2%98.7% | 137−34.5%98.5% | 146—98.6% | 171—98.8% | 188—99.6% | 210—99.5% | |
| Property, plant and equipment | 0.1—0.0% | 0.1−66.8%0.0% | 0.1−83.5%0.0% | 0.2−45.8%0.1% | 0.3−24.5%0.1% | 0.3−24.4%0.2% | 0.4−24.6%0.2% | 0.4−29.4%0.2% | 0.4−36.6%0.3% | 0.4—0.3% | 0.5—0.3% | 0.5—0.3% | 0.7—0.3% | |
| Right-of-use (leased) assets | — | — | — | — | 1.4−13.1%0.5% | — | — | — | 1.6+352%1.2% | 1.7—1.1% | 1.7—1.0% | 0.3—0.2% | 0.4—0.2% | |
| Other intangible assets | — | — | — | — | — | — | — | — | 0—0.0% | — | — | — | 0—0.0% | |
| Total assets | 496—100% | 496+127%100% | 527+177%100% | 336+113%100% | 280+101%100% | 218+47.7%100% | 190+9.8%100% | 157−16.5%100% | 139−33.9%100% | 148—100% | 173—100% | 188—100% | 211—100% | |
| Accounts payable | 0.8—0.2% | 0.8−84.0%0.2% | 1.3+49.5%0.2% | 1.5+42.1%0.5% | 2.7+1188%1.0% | 4.8+324%2.2% | 0.9−68.3%0.4% | 1.1−71.4%0.7% | 0.2−89.8%0.2% | 1.1—0.8% | 2.7—1.6% | 3.8—2.0% | 2.1—1.0% | |
| Current liabilities | 12—2.3% | 12−8.6%2.3% | 13+35.6%2.4% | 11+15.6%3.4% | 15+43.3%5.4% | 13+45.9%5.8% | 9.2−39.2%4.8% | 9.8−13.5%6.2% | 10−13.8%7.5% | 8.6—5.8% | 15—8.7% | 11—6.0% | 12—5.8% | |
| Long-term debt | 35—7.1% | 35+142%7.1% | 35+142%6.6% | 35—10.3% | 34—12.2% | 14—6.6% | 14—7.5% | — | — | — | — | — | — | |
| Lease liabilities (non-current) | 0.9—0.2% | 0.9−23.4%0.2% | 1.0−21.4%0.2% | 1.1−19.7%0.3% | 1.1−18.3%0.4% | 1.2−16.9%0.6% | 1.3−15.8%0.7% | 1.3+2950%0.9% | 1.4+701%1.0% | 1.5—1.0% | 1.5—0.9% | 0.0—0.0% | 0.2—0.1% | |
| Non-current liabilities | — | — | — | — | — | — | — | 5.3+29.7%3.4% | 5.3+21.2%3.8% | 5.8—4.0% | 5.7—3.3% | 4.1—2.2% | 4.4—2.1% | |
| Total liabilities | 52—10.5% | 52+58.6%10.5% | 53+82.9%10.1% | 52+242%15.4% | 55+248%19.7% | 33+127%15.0% | 29+39.2%15.2% | 15−2.1%9.6% | 16−4.5%11.3% | 14—9.8% | 21—12.0% | 15—8.2% | 17—7.9% | |
| Retained earnings | −726—−147% | −726—−147% | −695—−132% | −672—−200% | −649—−232% | −622—−285% | −603—−317% | −581—−369% | −561—−403% | −538—−364% | −515—−297% | −491—−261% | −466—−221% | |
| Shareholders' equity | 444—89.5% | 444+139%89.5% | 474+194%89.9% | 284+99.8%84.6% | 225+82.1%80.3% | 186+39.2%85.0% | 161+5.8%84.8% | 142−17.8%90.4% | 124−36.4%88.7% | 133—90.2% | 153—88.0% | 173—91.8% | 194—92.1% | |
| Total liabilities and equity | 496—100% | 496+127%100% | 527+177%100% | 336+113%100% | 280+101%100% | 218+47.7%100% | 190+9.8%100% | 157−16.5%100% | 139−33.9%100% | 148—100% | 173—100% | 188—100% | 211—100% | |
| Shares outstanding | 195—— | 195+103%— | 194+129%— | 130+67.3%— | 111+53.3%— | 96+34.4%— | 85+19.7%— | 78+9.8%— | 72+2.4%— | 71—— | 71—— | 71—— | 71—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 14−3.6%— | 2.9−19.4%— | 2.8−21.8%— | 3.4−15.9%— | 4.9*+47.3%19004% | 3.6+15.5%71080% | 3.6−17.3%71320% | 4.0+10.0%80300% | 3.4*+35.8%67080% | 3.1—61560% | 4.3—86220% | 3.7—73000% | 2.5*—6673% | |
| Cash from operating activities | −102—— | −38*—— | −24*—— | −21—— | −19*—−74800% | −12*—−237940% | −19*—−387000% | −17—−336800% | −18*—−365300% | −27*—−542360% | −18*—−362160% | −16—−327140% | −17*—−44684% | |
| Capital expenditure | −0.1—— | −0.1*—— | −0.0*—— | −0.0—— | −0.0*—−3.8% | 0*—0.0% | — | — | — | — | — | — | 0*—0.0% | |
| Cash from investing activities | −301—— | 3.5*—— | −221*−319%— | −3.7—— | −79*−681%−304454% | −149*−12554%−2986420% | 101*—2022140% | −5.1—−102020% | 14*—272640% | 1.2*—23980% | −3.7*—−73920% | −40—−790420% | −8.0*—−21511% | |
| Debt issued | — | — | — | — | 20*—76923% | 0*—0.0% | — | — | — | — | — | — | — | |
| Shares issued | 71—— | 0*−100%— | −0.1*−100%— | 8.7−74.8%— | 62r62*—238242% | 40r40*—790340% | 38r38*—750500% | 35—694960% | — | — | — | — | 73*—196592% | |
| Cash from financing activities | 371+173%— | 0.1*−99.8%— | 211*+304%— | 78+130%— | 81*+704%312038% | 39*+14693%786980% | 52*—1044880% | 34—682380% | 10*−86.1%201700% | 0.3*—5320% | −0.0*—−920% | −0.3—−5220% | 73*—196632% | |
| Change in cash | −32−209%— | −34*—— | −35*−126%— | 54+342%— | −17*−421%−67215% | −122*—−2437380% | 134*—2680020% | 12—243560% | 5.5*−88.7%109040% | −26*—−513060% | −22*—−437000% | −56—−1122780% | 48*—130438% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Where Altimmune, Inc. operates: 3 countries#
Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 4 subsidiaries on file.
| Country | Presence | Revenue there |
|---|---|---|
| 🇺🇸 USA | Headquarters2 offices2 subsidiaries | — |
| 🇦🇺 Australia | 1 subsidiary | — |
| 🇬🇧 UK | 1 subsidiary | — |
Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided
Executive pay at Altimmune, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Vipin Garg | $8.0 M | $1.8 M | $2.4 M | $22 |
| 2024Jerome Benedict Durso | $6.1 M | $2.5 M | $2.4 M | $79 |
| 2023Jerome Benedict Durso | $5.5 M | $2.1 M | $2.6 M | $123 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Altimmune, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Directors and officers 7 · Material agreement 5 · Agreement ended 1 · New debt 3 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 9
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| New debt | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Directors and officers | 8-K | |
| Material agreementNew debtResults announced | 8-K | |
| Material agreementAgreement ended | 8-K | |
| Directors and officers | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debtResults announced | 8-K | |
| Directors and officersResults announced | 8-K | |
| Directors and officers | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026
Acquisitions and funding#
2 private funding rounds before listing
Private share sales · funding history
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Altimmune, Inc.#
$0 spent on lobbying the US Congress and federal agencies in 2022.
Lobbying firms hired in 2022
BGR Government Affairs
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2022 | $0 | — | 1 |
| 2021 | $250 K | — | 6 |
| 2020 | $315 K | — | 7 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Altimmune, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Altimmune, Inc.#
1 labor condition applications certified in fiscal 2020 for 1 positions, at a median wage of $127 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior BiostatisticianBiostatisticians | 1 | $127 K |
Where: Gaithersburg, MD 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Altimmune, Inc.
Discuss Altimmune, Inc.#
2 automatic updates and 0 member comments. Sign in to comment and react.
- Results announced on 12 November 2026automatic update · Nov 12, 2026
Altimmune, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $32 million.
- Mutual funds: 112 funds hold $130 millionautomatic update · Jul 31, 2026
112 mutual funds in 1 country hold shares of Altimmune, Inc. worth $130 million, about 22.2% of the company (funds' newest reports, up to 31 July 2026). Since their previous reports 76 funds added shares and 19 sold; on balance they bought $40 million. Share splits are not counted as trading.
How Altimmune, Inc. compares in Biotechnology
- Market cap$459 M · higher than 57% of 726
- Revenue$0 M · higher than 14% of 647
- Revenue growth100.0% · higher than 82% of 438
- Price / book2.0× · lower than 58% of 534
- FCF yield-14.7% · higher than 50% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Altimmune, Inc.🇺🇸 | $459 M | — | — | +100.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 16, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As on June 2022
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Altimmune, Inc.? Verify and update this profile — free
Show Altimmune, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.